Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 97,116

Document Document Title
WO/2014/055932A1
The present invention is an ingestable blended formulation which will cause a series of distinct biochemical changes in-vivo; initiate desirable psychological consequences in that person; and induce an observable increase in cognitive fu...  
WO/2014/055055A1
A pharmaceutical composition for parenteral administration containing the active ingredient 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml for th...  
WO/2014/055949A1
The invention generally features isolated platelets, compositions, methods, and kits useful for targeted delivery of one or more therapeutic agents to a site of injury, inflammation, disease, or disorder. Also featured are methods and ki...  
WO/2014/055047A1
The present invention is related to pharmaceutical compositions comprising idebenone and donepezil for use in symptomatic treatment of cerebral arteriosclerosis, symptoms following stroke and cerebral hemorrhage, age-associated cognitive...  
WO/2014/054965A1
The invention relates to the field of pharmacology and practical medicine, and specifically to the combined use of medicinal preparations, with neuro-tropic action, alleviating the manifestation of mental, behavioural and cognitive di...  
WO/2014/053418A9
The present invention relates to a method for obtaining mesenchymal stem cells (MSCs) from mammalian tissue or body fluid, comprising isolating said MSCs from tissue or body fluid and expanding said isolated MSCs in multiple cultivation ...  
WO/2014/054634A1
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/053418A3
The present invention relates to a method for obtaining mesenchymal stem cells (MSCs) from mammalian tissue or body fluid, comprising isolating said MSCs from tissue or body fluid and expanding said isolated MSCs in multiple cultivation ...  
WO/2014/053857A1
Disclosed herein are mono or di-succinate compounds where one or both of the acid groups in the succinate core are protected in the form of biologically labile moieties, and the use of said compounds to enhance mitochondrial function. Th...  
WO/2014/054005A3
The invention involves the preparation of cholesterol lecithin nanosomes, without propylene glycol, from the complex formed by quercetin (or another flavonol or flavone or a derivative thereof) and 2-hydroxypropyl-β-cyclodextrin, by mea...  
WO/2014/053580A1
The present invention relates to the anticonvulsant activity of GSK-3βinhibitors and the use of GSK-3β inhibitors as agents for the treatment of neurological disorders characterized by seizures such as epilepsy.  
WO/2014/054651A1
A sleep-improving agent, a non-REM sleep time-increasing agent and a sedative agent, each of which comprises a fat-soluble anti-oxidative substance and a bivalent metal as active ingredients.  
WO/2014/055644A3
The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature terminatio...  
WO/2014/055629A1
The present disclosure provides compounds of formula (I): compositions comprising these compounds, and methods of using these compounds in a variety of applications, such as treatment or suppression of diseases associated with decreased ...  
WO/2014/053409A1
The present invention relates to compounds of general formula wherein R1 hydrogen, lower alkyl, halogen or lower alkyl substituted by halogen; R2 is hydrogen or halogen; X1 is N or CH; X2 is N or CH; with the proviso that only one of X1 ...  
WO/2014/055515A1
The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.  
WO/2014/053420A1
The present invention relates to a method for the isolation of mesenchymal stem cells from the blood of mammals, comprising the isolation of mesenchymal stem cells from the blood-interphase of blood samples and preserving said cells in a...  
WO/2014/053210A1
The invention relates to compounds of formula I: wherein R, X and Y, have the meanings given in claim 1. The compounds useful e.g. in the treatment of autoimmune and/or inflammatory disorders, such as multiple sclerosis.  
WO/2014/055916A1
The present invention relates to substituted aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.  
WO/2014/051056A1
The purpose of the present invention is to provide: crystals of (S,E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl- pyrimidin-2-ylamino)phenyl]pent-4-enoic acid having excellent chemical and physical stability or a pharmacologically accepta...  
WO/2014/048865A1
The invention provides novel compounds having the general formula (I) wherein R1, Y, A, W, R2, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2014/050779A1
To provide a combination therapy for cancer, which comprises a combination of a GSK3 inhibitor and an anti-DR5 antibody. Provided are a pharmaceutical product and a combination therapy, each of which comprises a combination of various an...  
WO/2014/052896A1
This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprisi...  
WO/2014/050003A1
[Problem] To provide a substance capable of safely and effectively modulating expression of a period gene. [Solution] An expression modulator for a period gene containing Pelargonium plant extract as an effective component.  
WO/2014/052415A3
Provided herein are methods of diagnosing depressive disorders in a subject by comparing a CDP-diacylglycerol synthase 1 enzyme activity or expression level to enzyme activity or expression level of CDP-diacylglycerol synthase 1 in a con...  
WO/2014/052789A1
The invention relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.  
WO/2014/052849A1
The invention relates generally to novel compositions and methods comprising a scyllo-inositol compound and one or both of valproic acid compound and lamotrigine. The compositions and methods provide beneficial effects in the treatment o...  
WO/2014/052859A1
The present invention relates to intranasally administered pharmaceutical compositions for the treatment of headaches, such as migraines. Such pharmaceutical compositions comprise benzyl alcohol or a combination of benzyl alcohol and tet...  
WO/2014/052837A1
A drug delivery device comprising a non-erodible, non-porous housing member defining a reservoir is provided. The reservoir is loaded with a dry formulation of a selected salt of a neuroleptic agent. The housing member has one or more po...  
WO/2014/050084A1
The purpose of the invention is to create a compound that selectively activates liver glucokinase and in particular to provide a drug having low hypoglycemic risk for the treatment and prevention of diabetes and impaired glucose toleranc...  
WO/2014/052766A1
Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dem...  
WO/2014/048380A1
A preparation method of an agomelatine solid preparation comprises: mixing agomelatine or pharmaceutically acceptable salts with cross-linked polyvinylpolypyrrolidone; hot-melting the mixture to prepare particles; and then mixing the par...  
WO/2014/052394A1
Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (he pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and ...  
WO/2014/048945A1
The present invention relates to BET protein-inhibiting 5-aryl triazole azepines, particularly BRD4-inhibiting 5-aryl triazole azepines of general formula (I) in which R1, R2, R3 and R4 have the meanings indicated in general formula (I)....  
WO/2014/049556A3
The invention relates to a method of regulating neurotrophin-tyrosine kinase receptor signalling in a cell comprising modulating the interaction between the juxtamembrane region of the intracellular domain of the neurotrophin receptor p7...  
WO/2014/048033A1
The present invention relates to polymorphic forms of the compound of Formula (I) (i.e., ethyl 2-cyano-3,12-dioxoIeana-1,9(1l)-dien-28-oate (CDDO ethyl ester)) and methods of using them for treating a variety of disease states such as ca...  
WO/2014/052933A1
This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridop...  
WO/2014/049471A1
The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an ef...  
WO/2014/049366A1
Provided is a method of treating and/or preventing Wolfram Syndrome (WS)-related neurodegeneration (i.e. of Wolfram Syndrome-Associated Neuronal Degeneration), by increasing the expression and/or functional activity of p21. A method of s...  
WO/2014/047707A1
The present invention relates to a compound of formula (I) or to a pharmaceutically acceptable salt thereof with analgesic activity. In particular, the compounds according to the present invention are useful for treating or preventing ac...  
WO/2014/049133A1
The present invention relates to indole derivatives useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive a...  
WO/2014/052427A1
The present invention relates to a method of treating psychiatric symptoms in a subject having a NMDA receptor and a NE receptor which includes administering d-methadone, d-methadol, d-alpha-acetylmethadol, l-alpha-acetylmethadol, d-alph...  
WO/2014/052807A1
Methods for alleviating symptoms related to Multiple Sclerosis by administration of apoaequorin are provided by the present invention. Such symptoms include, for example, sleep quality, energy quality, mood quality, memory quality or pain.  
WO/2014/052398A1
The present invention relates to spirocyclic indane imidazole 4-amines and their use as inhibitors of the β-secretase enzyme (BACEl) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic...  
WO/2014/052669A1
Described herein, inter alia, are compositions and methods of using the same for modulating the activity of Ire1.  
WO/2014/051388A1
The present invention relates to a pharmaceutical composition comprising a sulfamide derivative having an adamantyl group as an active ingredient for preventing or treating brain diseases or ischemic heart diseases. The sulfamide derivat...  
WO/2014/048370A1
Methods and compounds for treating, inhibiting, and preventing traumatic brain injury are provided. Methods include administering 7,8-dihydroxyflavone and derivatives thereof.  
WO/2014/051567A1
Composition containing a chimeric neuregulin polypeptides and method of making such polypeptides are disclosed. The chimeric neuregulin comprises a first moiety of at least 10 amino acids, wherein the first moiety is derived from a first...  
WO/2014/048165A1
Disclosed is a compound as a potassium channel modulator, which is a compound of general formula (I) or a pharmaceutically acceptable salt thereof. Such compound can be used to prepare drugs for increasing the flow of ions in potassium c...  
WO/2014/052461A1
The invention features compositions for use in increasing neuron or neurite growth, including for the treatment of Central Nervous System (CNS) injury, such as human arylsulfatase B.  

Matches 651 - 700 out of 97,116